ResMed (RMD) - FREE Research Report Sandercock Brett who is Chief Financial Officer at ResMed sold 15,000 shares at $51.06 on Nov. 22, 2013. Following this transaction, the Chief Financial Officer owned 94,902 shares meaning that the stake was reduced by 13.65% with the 15,000 share transaction. The shares most recently traded at $51.05, down $0.01, or 0.01% since the insider transaction. Historical insider transactions for ResMed go as follows:
4-Week # shares sold: 35,563
12-Week # shares sold: 36,563
24-Week # shares sold: 37,063
The average volume for ResMed has been 1.2 million shares per day over the past 30 days. ResMed has a market cap of $7.2 billion and is part of the health care sector and health services industry. Shares are up 22.88% year to date as of the close of trading on Friday. ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The stock currently has a dividend yield of 1.97%. The company has a P/E ratio of 23.4. Currently there are 7 analysts that rate ResMed a buy, no analysts rate it a sell, and 4 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on RMD - FREETheStreet Quant Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.